Similar articles for PMID: 15653658

Year	Number of Results
1950	1
1955	1
1956	1
1962	1
1967	1
1969	1
1976	2
1979	2
1980	2
1981	1
1982	1
1984	2
1986	2
1987	1
1989	1
1991	2
1994	2
1996	1
1997	3
1998	3
1999	5
2000	1
2001	9
2002	13
2003	8
2004	14
2005	12
2006	19
2007	8
2008	11
2009	5
2010	17
2011	15
2012	16
2013	18
2014	18
2015	21
2016	13
2017	10
2018	12
2019	12
2020	7
2021	10
2022	6
2023	3
2024	0

1

Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.

Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, Kvols LK, Krenning EP, Jamar F, Pauwels S. Barone R, et al. J Nucl Med. 2005 Jan;46 Suppl 1:99S-106S. J Nucl Med. 2005. PMID: 15653658 Free article. Clinical Trial.

2

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, Barone R, Walrand S, Kooij PP, Bakker WH, Lasher J, Krenning EP. Valkema R, et al. J Nucl Med. 2005 Jan;46 Suppl 1:83S-91S. J Nucl Med. 2005. PMID: 15653656 Free article. Clinical Trial.

3

Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.

Barone R, Walrand S, Konijnenberg M, Valkema R, Kvols LK, Krenning EP, Pauwels S, Jamar F. Barone R, et al. Nucl Med Commun. 2008 Mar;29(3):283-90. doi: 10.1097/MNM.0b013e3282f3d03e. Nucl Med Commun. 2008. PMID: 18349800 Clinical Trial.

4

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, Baio SM, Sansovini M, Paganelli G. Bodei L, et al. Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1847-56. doi: 10.1007/s00259-008-0778-1. Epub 2008 Apr 22. Eur J Nucl Med Mol Imaging. 2008. PMID: 18427807 Clinical Trial.

5

A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.

Konijnenberg MW, Bijster M, Krenning EP, De Jong M. Konijnenberg MW, et al. J Nucl Med. 2004 Jul;45(7):1260-9. J Nucl Med. 2004. PMID: 15235075 Free article.

6

Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.

Kulkarni HR, Schuchardt C, Baum RP. Kulkarni HR, et al. Recent Results Cancer Res. 2013;194:551-9. doi: 10.1007/978-3-642-27994-2_32. Recent Results Cancer Res. 2013. PMID: 22918782

7

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.

Helisch A, Förster GJ, Reber H, Buchholz HG, Arnold R, Göke B, Weber MM, Wiedenmann B, Pauwels S, Haus U, Bouterfa H, Bartenstein P. Helisch A, et al. Eur J Nucl Med Mol Imaging. 2004 Oct;31(10):1386-92. doi: 10.1007/s00259-004-1561-6. Epub 2004 Jun 3. Eur J Nucl Med Mol Imaging. 2004. PMID: 15175836 Clinical Trial.

8

⁹⁰Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy.

Menda Y, Madsen MT, O'Dorisio TM, Sunderland JJ, Watkins GL, Dillon JS, Mott SL, Schultz MK, Zamba GKD, Bushnell DL, O'Dorisio MS. Menda Y, et al. J Nucl Med. 2018 Nov;59(11):1692-1698. doi: 10.2967/jnumed.117.202903. Epub 2018 Mar 9. J Nucl Med. 2018. PMID: 29523629 Free PMC article. Clinical Trial.

9

Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.

Van Binnebeek S, Baete K, Vanbilloen B, Terwinghe C, Koole M, Mottaghy FM, Clement PM, Mortelmans L, Haustermans K, Van Cutsem E, Verbruggen A, Bogaerts K, Verslype C, Deroose CM. Van Binnebeek S, et al. Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1141-57. doi: 10.1007/s00259-013-2670-x. Epub 2014 Mar 26. Eur J Nucl Med Mol Imaging. 2014. PMID: 24668274 Clinical Trial.

10

Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.

Förster GJ, Engelbach MJ, Brockmann JJ, Reber HJ, Buchholz HG, Mäcke HR, Rösch FR, Herzog HR, Bartenstein PR. Förster GJ, et al. Eur J Nucl Med. 2001 Dec;28(12):1743-50. doi: 10.1007/s002590100628. Epub 2001 Oct 20. Eur J Nucl Med. 2001. PMID: 11734910

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

280 results

Results by year